Tandem Diabetes Care Inc (TNDM) achieves highest quarterly sales in history, driven by strong US and international growth, ...

Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the ...

At the heart of Tandem's recent success is its expanding product portfolio, with the Mobi insulin pump system taking center stage. The Mobi launch has been particularly well-received, contributing ...

Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...

This is a result of strong execution of our strategy to drive growth through our expanding product portfolio and is underscored by outstanding feedback on our newly launched Tandem Mobi.